Ignite Creation Date:
2024-05-05 @ 11:54 PM
Last Modification Date:
2024-10-26 @ 10:41 AM
Study NCT ID:
NCT01449461
Status:
COMPLETED
Last Update Posted:
2021-08-17
First Post:
2011-09-30
Brief Title:
A Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase ALKEpidermal Growth Factor Receptor EGFR Inhibitor Brigatinib AP26113
Sponsor:
Ariad Pharmaceuticals
Organization:
Takeda
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-09-20
Start Date Type:
ACTUAL
Primary Completion Date:
2015-11-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-02-18
Completion Date Type:
ACTUAL
First Submit Date:
2011-09-30
First Submit QC Date:
October 6 2011
Study First Post Date:
2011-10-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2017-06-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-26
Last Update Post Date:
2021-08-17
Last Update Post Date Type:
ACTUAL